¶à°·(Polyamines, PAs)ÊÇÒ»ÀàµÍ·Ö×ÓÁ¿Ö¬·¾×庬µª¼î£¬Æձ鱣´æÓÚÖ²Îï¡¢¶¯ÎP΢ÉúÎïÖУ¬°üÀ¨¸¯°·¡¢ÑǾ«°·¡¢¾«°·¼°ÆäÑÜÉúÎï¡£¶à°·Óëϸ°ûÉú³¤·¢Óý¡¢ºËËá´úл¡¢ÂÑ°×ÉúÎïºÏ³ÉÒÔ¼°ÌÇ¡¢Ö¬ÖÊ¡¢¼¤ËØ´úлµÈÓйأ¬ÔÚÉúÎïÌåÉú³¤ºÍ·¢ÓýÀú³ÌÖÐÊ©Õ¹×ÅÖ÷Òª×÷Óá£Òò´Ë¶à°·¼ì²âÔÚÑо¿Ö²ÎïÉú³¤·¢ÓýºÍÁÙ´²Õï¶ÏµÈ·½Ãæ¾ùÓÐÖ÷ÒªµÄÑо¿ÒâÒå¡£
¸ßµÈÖ²ÎﺬÓеĶషÖ÷ÒªÓÐ5ÖÖ£¬¸¯°·(putrescine, Put)¡¢ÑǾ«°·(Spermidine, Spd)¡¢¾«°·(Spermine, Spm)¡¢Ê¬°·(Cadaverine, Cad)¼°ö°·(Agmatine, Agm)¡£Èç´ó¶¼Ñо¿Åú×¢£¬¶à°·ÊÇÖ²ÎïµÄÒ»ÖÖÉú³¤µ÷ÀíÒò×Ó£¬¼ÓÈëÖ²ÎïµÄÉú³¤·¢Óý¡¢ÐÔ±ð·Ö½â¡¢¹ûʵ³ÉÊìÓëÐàÂõÒÔ¼°Ë³Ó¦Äæ¾³µÈÖ÷ÒªÐÄÀíÀú³Ì¡£Ö²ÎïÖУ¬¶à°·Í¨³£ÒÔ×ÔÓÉ»òÕßÓëôÇ»ùÈâ¹ðËá¹²éîµÄ״̬±£´æ¡£¶à°·ÔÚÖ²ÎïÉú³¤·¢ÓýÀú³ÌÖÐÓÐÒÔÏÂ×÷Óãº
Ò»¡¢ÔÚϸ°ûÀú³ÌÖУººÃ±Èϸ°ûÉú³¤£¬·Ö½âºÍ»ùÒò±í´ï£¬DNAºÍÂѰ׵ĺϳɵȷ½ÃæÓÐÖ÷Òª×÷Óá£
¶þ¡¢ÐÄÀíÀú³ÌÖУºÀýÈ磬Æ÷¹ÙµÄ±¬·¢£¬ÅßÌ¥µÄÐγɣ¬»¨µÄ±¬·¢ºÍ·¢Óý£¬Ò¶Æ¬µÄÐàÂõ£¬»¨·Û¹ÜµÄÉú³¤£¬¹ûʵµÄ·¢ÓýºÍ³ÉÊìµÈ¡£
Èý¡¢¼ÓÈëÖÖÖÖвÆÈÏìÓ¦£º¶à°·¿ÉÒÔÓÕµ¼Ò»Ñõ»¯µª(Nitric Oxide, NO)ºÍ»îÐÔÑõ(Reactive Oxygen Species, ROS)µÄȺ¼¯¡£
¶à°·ºÏ³Éͨ·
¶à°·¼°ÆäºÏ³Éͨ·ÎïÖʼì²âÁбí
? Ñù±¾ÒªÇó
Ö²Îï×éÖ¯£º1 g/sample
¶¯Îï¼°ÁÙ´²×éÖ¯Ñù±¾£º200 mg/sample
ѪÇ塢Ѫ½¬£º200 ¦ÌL/sample
ÄòÒº£º200 ¦ÌL/sample
ϸ°û¡¢Î¢ÉúÎ1X107 cells/sample
·à±ã¡¢³¦µÀÄÚÈÝÎ200 mg/sample
? Öü´æºÍÔËÊä
Òºµª»ò-80¡ãCÉúÑÄ£»×ãÁ¿¸É±ùÔËÊ䣬×èÖ¹Öظ´¶³ÈÚ
? ¼ì²âƽ̨
Triple Quadrupole 6460, Agilent
? ͨÀýÏîÄ¿ÖÜÆÚ
ʵÑé¼ì²â£º30¸ö×ÔÈ»ÈÕ£¨´ÓÊÕµ½¿Í»§Ô¤¸¶¿î²¢ÊÕµ½ÑùÆ·Ö®ÈÕÆð£©
Êý¾ÝÆÊÎö£º5¸ö×ÔÈ»ÈÕ
- Ö²ÎïÉú³¤·¢ÓýÑо¿
- Ö×Áö¼²²¡Õï¶Ï¼°ÁÆЧԤºóµÄÐÄÀíÖ¸±ê¾ò¿Í
? ÅÁ½ðɲ¡¶à°·´úлÆ×£ºÒ»¸öÓÐǰ;µÄÉúÎï±ê¼ÇÎï
Ñо¿¹¤¾ß£º ÅÁ½ðÉ»¼Õß
ÆÚ¿¯£º Annals of Neurology
Ó°ÏìÒò×Ó£º 10.422
ʱ¼ä£º 2019Äê
Ë¥×ÜÊÇÅÁ½ðɲ¡(Parkinson¡¯s Disease, PD)µÄ×î¸ßΣÏÕÒòËØ£¬ÆäÏÖÔÚµÄÖÎÁƽöÏÞÓÚÖ¢×´»º½â¡£ÓëÅÁ½ðɲ¡µÄÄêËêÏà¹ØΣº¦Ïà¹ØµÄѪҺÉúÎï±ê¼ÇÎï¿ÉÒÔÓÐÓüà²â¼²²¡Àú³Ì£¬²¢¿ÉÓÃÓÚ¿ª·¢ÖÎÁÆÒªÁì¡£ÔÚÐÄÀíÌõ¼þÏ£¬ÑǾ«°·(Spermidine, Spd)ºÍ¾«°·(Spermine, Spm)ͨ¹ý×ÔÊÉÓÕµ¼ÊµÑéÌá¸ßÊÙÃü¡£Òò´Ë£¬ÎÒÃÇÆÀ¹ÀÁËÿ¸ö¶à°·´úлÎï×÷ΪÄêËêÏà¹Ø¡¢Õï¶ÏÐÔºÍÑÏÖØˮƽÏà¹ØPDÉúÎï±ê¼ÇÎïµÄÄÜÁ¦¡£
? Ñо¿Ð§¹û
ÔÚÐÐÁÐAÖУ¬PD»¼ÕßN8-ÒÒõ£ÑǾ«°·ºÍn-ÒÒõ£¸¯°·Ë®Æ½»®·ÖÏÔÖøºÍÇá¶ÈÉý¸ß¡£ÔÚÐÐÁÐBÖУ¬PD»¼Õߵľ«°·Ë®Æ½ºÍ¾«°·/ÑǾ«°·±ÈÖµÏÔÖø½µµÍ£¬°éÓиßÒÒõ£»¯¡£±ðµÄ£¬N1¡¢n8-¶þÒÒõ£ÑǾ«°·Ë®Æ½¾ßÓÐ×î¸ßµÄÕï¶Ï¼ÛÖµ£¬ÓëDTI¶¨Á¿µÄH&Y¡¢UPDRS-IIIºÍÖáË÷±äÐÔÏà¹Ø¡£±ÈÕÕ×éµÄ¾«°·/ÑǾ«°·±ÈÖµËæÄêËêµÄÔöÌí¶øϽµ£¬µ«ÔÚÅÁ½ðɲ¡ÖÐʼÖÕÊܵ½ÒÖÖÆ¡£Ôڶష´úлÎïÖУ¬¾«°·ÊÇ×îÇ¿µÄ×ÔÊÉÓÕµ¼Òò×Ó£¬ÓÈÆäÔÚSH-SY5Yϸ°ûÖС£Óë±ÈÕÕ×éÏà±È£¬ÔÚ±àÂëÓ뾫°·/ÑǾ«°·´úлÏà¹ØµÄøµÄ5¸ö»ùÒòÖÐûÓз¢Ã÷ÏÔÖøµÄÒÅ´«±äÒì¡£
? Ñо¿Ë¼Ð÷
? Ч¹ûչʾ
ʹÓÃÐÐÁÐA¾ÙÐеÄ×ۺϴúл×éÆÊÎöÏÔʾ£¬Ó뿵½¡±ÈÕÕ×éÏà±È£¬PD»¼ÕßµÄN8-ÒÒõ£ÑǾ«°·(N8-AcSpd)ºÍN-ÒÒõ£¸¯°·(N-AcPut)ˮƽÉý¸ß¡£N8-AcSpdºÍN-AcPutÓëH&YºÍUPDRS-IIIÏÔÖøÏà¹Ø£¨Í¼1£©¡£¶ÔÐÐÁÐB¾ÙÐÐѪÇåÆÊÎö£¬Ð§¹ûÅú×¢´ó´ó¶¼ÒÒõ£»¯¶à°·ÐÎʽÔÚPDÖÐÏÔÖøÉý¸ß¡£ÇÒSpdÔÚPDÖÐÏÔÖø¸ßÓÚ±ÈÕÕ×飬¶øPD×éSpmÏÔÖø½µµÍ¡£ROCÇúÏßÆÊÎöÏÔʾ£¬7Öֶష´úлÎï¶ÔPD¡¢PSPºÍAD¾ßÓнÏÇ¿µÄÕï¶ÏÄÜÁ¦£¨Í¼3£©¡£TBSSÆÊÎö·¢Ã÷PD»¼Õß¾LEDÕý³£»¯ºó´óÄÔÆÕ±é°×ÖÊÇøDiAcSpdºÍFAÏÔÖøÕýÏà¹Ø¡£Spm/Spd±ÈֵЧ¹ûÏÔʾPD»¼ÕßÔÚÈκÎÄêËê¶ÎµÄSpm/Spd±ÈÖµ½Ï¿µ½¡±ÈÕÕ×é¾ùÏÔÖø½µµÍ£¨Í¼3£©¡£¼ì²âÈýÖֶషºÍÎåÖÖÒÒõ£»¯ÐÎʽ¶ÔSH-SY5Yϸ°û×ÔÊɵÄÓ°Ïì·¢Ã÷SpmºÍSpdÔöÌíÁËLC3-IIˮƽ¡£Åú×¢Spm/SpdˮƽµÄ½µµÍ¿ÉÄÜ»áÓ°ÏìPD»¼ÕßµÄ×ÔÊÉ»îÐÔ¡£
ͼ1. DiAcSpd¡¢N8-AcSpdºÍDiAcSpmˮƽÓëH&YÆÀ¹ÀµÄÅÁ½ðɲ¡
ÑÏÖØˮƽ³ÊÕýÏà¹Ø£¬¶øÆäËû¶à°·´úлÎïÔòûÓÐÏà¹ØÐÔ
ͼ2. BÐÐÁÐÖÐËùÓÐѪÇå¶à°·´úлÎïµÄÊÜÊÔÕßÊÂÇéÌØÕ÷ÇúÏß
ºÍÏìÓ¦µÄÕï¶ÏÅÁ½ðɲ¡ÕæÑôÐÔÂʵÄAUCͳ¼ÆÁ¿
ͼ3. ̫ͨ¹ýÎö±ÈÕÕ×éºÍÅÁ½ðɲ¡×éÖ®¼äµÄз½²îÀ´ÆÀ¹À½»»¥×÷ÓÃ
? ²Î¿¼ÎÄÏ×
Saiki S, Sasazawa Y, Fujimaki M, Kamagata K, Kaga N, Taka H, Li Y, Souma S, Hatano T, Imamichi Y, Furuya N, Mori A, Oji Y, Ueno SI, Nojiri S, Miura Y, Ueno T, Funayama M, Aoki S, Hattori N. A metabolic profile of polyamines in Parkinson disease: A promising biomarker. Ann Neurol. 2019 Aug;86(2):251-263.